Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) shares closed more than 5% higher on Thursday following the company’s pre-announcement, according to which its Q4 Nurtec ODT end-user revenue came in at $190 million (up 48% quarter-over-quarter), beating the consensus estimate of $140 million. The company mentioned no material inventory level changes, suggesting strong organic growth.

Analysts at Wedbush continue to see the dual prevention/treatment label as a key differentiation point for Nurtec ODT, and raised their price target on the company’s shares to $149 from $144 following the pre-announcement.